Just a summary of all the news articles that we could source from different places. A good way to make an investment decision is also to look at how actively the company is engaging with news sources to keep them in the news. In this day and age its critical to have a media presence.
Please consider a small donation if you think this website provides you with relevant information
| Date | Title | Source |
|---|---|---|
| 2024-03-21 5:31:10 am | LIXTE Provides Update on Progress with LB-100 as a PP2A Inhibitor to Enhance Chemotherapy and Immunotherapy Cancer Treatments | GlobeNewsWire |
| 2024-02-27 5:30:0 am | Professor René Bernards to Present New Pre-Clinical Data on LIXTE’s LB-100 at Joint Conference of European and American Associations for Cancer Research | GlobeNewswire |
| 2024-02-26 5:30:0 am | LIXTE Biotechnology Enters into Exclusive Immune Oncology Patent License Agreement with NINDS and NCI | GlobeNewswire |
| 2024-01-29 5:30:0 am | First Patient Dosed with LIXTE’s LB-100 and GSK’s Immunotherapy Dostarlimab-gxly in Ovarian Clear Cell Carcinoma Trial | GlobeNewswire |
Please consider a small donation if you think this website provides you with relevant information